U.S. Markets closed

Adaptive Biotechnologies Corporation (ADPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
65.09-0.56 (-0.85%)
At close: 4:00PM EST

65.05 -0.04 (-0.06%)
After hours: 4:33PM EST

Full screen
Loading interactive chart...
  • The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue
    Benzinga

    The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11) * 10X Genomics Inc (NASDAQ: TXG) * AbbVie Inc (NYSE: (ABBV) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) * AtriCure Inc. (NASDAQ: ATRC) (reacted to the company's preliminary fourth-quarter results) * Bioanalytical Systems, Inc. (NASDAQ: BASI) * Biodesix Inc (NASDAQ: BDSX) * C4 Therapeutics Inc (NASDAQ: CCCC) * CareDx Inc (NASDAQ: CDNA) (announced preliminary fourth-quarter results) * Celsius Holdings, Inc. (NASDAQ: CELH) * Chimerix Inc (NASDAQ: CMRX) * Curis, Inc. (NASDAQ: CRIS) * Dyne Therapeutics Inc (NASDAQ: DYN) (announced positive preclinical data from its myotonic dystrophy type 1 program) * Edap Tms SA (NASDAQ: EDAP) * Eli Lilly And Co (NYSE: LLY) (announced positive data from midphase study of its investigational asset in treating early symptomatic Alzheimer's) * ESSA Pharma Inc (NASDAQ: EPIX) * EXACT Sciences Corporation (NASDAQ: EXAS) (reacted to preliminary fourth-quarter results) * Eyenovia Inc (NASDAQ: EYEN) * Guardant Health Inc (NASDAQ: GH) * Johnson & Johnson (NYSE: JNJ) * Kaleido Biosciences Inc (NASDAQ: KLDO) * Oxford Immunotec Global PLC (NASDAQ: OXFD) * Pacira Biosciences Inc (NASDAQ: PCRX) * Supernus Pharmaceuticals Inc (NASDAQ: SUPN) * Syneos Health Inc (NASDAQ: SYNH) * Theratechnologies Inc (NASDAQ: THTX) * Twist Bioscience Corp (NASDAQ: TWST) * United Therapeutics Corporation (NASDAQ: UTHR) * Vascular Biogenics Ltd (NASDAQ: VBLT) * Xencor Inc (NASDAQ: XNCR)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Jan. 11) * AbCellera Biologics Inc (NASDAQ: ABCL)Stocks In Focus T2 Biosystems' Molecular Diagnostic Test Capable Of Detecting Multiple Coronavirus Variants T2 Biosystems Inc (NASDAQ: TTOO) announced that its T2SARS-CoV-2 Panel, a molecular diagnostic test that detects SARS-CoV-2, is capable of detecting multiple variants of the SARS-CoV-2 virus most recently identified in the U.K., South Africa and the U.S."I'm proud that we can confidently say, after extensive analysis, that our T2SARS-CoV-2 Panel, which has demonstrated clinical sensitivity of 95 percent and specificity of 100 percent, can continue to help impact lives by detecting multiple variants of the SARS-CoV-2 virus," T2 Biosystems President and CEO John Sperzel said in a statement. The stock was up 39.38% premarket Tuesday to $2.23.GSK, Vir To Begin COVID-19 Antibody Study In Patients With Mild-To-Moderate Infection GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild-to-moderate COVID-19 in a Phase 1b/2a clinical trial.VIR-7832 is a neutralizing COVID-19 antibody that showed promising results in preclinical studies. It enhanced the ability to clear infected cells and possessed potential to enhance virus-specific T-cell function, which could help treat and/or prevent COVID-19 infection.The trial is expected to begin in the first quarter at multiple sites across the U.K.GlaxoSmithKline shares were down 0.53% premarket at $37.73. Roche To Present Positive Results For Late-Stage Kidney Cancer Combo Therapy Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) announced updated overall survival data from the Phase 3 IMbrave150 study evaluating Tecentriq in combination with Avastin, compared with Bayer AG's (OTC: BAYRY) Nexavar, in people with unresectable hepatocellular carcinoma.The data showed that after a median follow-up of 15.6 months, Roche's combo reduced the risk of death by 34%, with a median overall survival of 19.2 months compared with 13.4 months for Nexavar."These results show that Tecentriq in combination with Avastin provides the longest survival that we've ever seen in a front-line Phase III study in unresectable HCC," said Levi Garraway, Roche's chief medical officer.Roche will present the data at the ASCO Gastrointestinal Cancers Symposium from 3:30-4:15 p.m. Sunday.Novartis In-Licenses BeiGene's Cancer Drug For $650M Novartis AG (NYSE: NVS) and Beigene Ltd (NASDAQ: BGNE) signed a strategic collaboration agreement to in-license BeiGene's tislelizumab in major markets outside of China. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages.The agreement provides for Novartis obtaining the development and commercialization rights to tislelizumab in the U.S., Canada, Mexico, the EU, U.K., Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan in exchange for an upfront payment of $650 million plus royalties and milestone payments. BeiGene will retain the rights to tislelizumab in China and other countries. The transaction has been approved by the boards of both companies.BeiGene shares were up 2.12% premarket at $284.84. Amneal To Buy Specialty Pharms Company Kashiv Amneal Pharmaceuticals Inc (NYSE: AMRX) announced an agreement to acquire a 98% interest in Kashiv Specialty Pharmaceuticals for a cash payment of $70 million at closing and a payment of $30 million at the one-year anniversary point of the deal. The company is engaged in the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs.Kashiv is also eligible to receive up to an additional $8 million in contingent payments upon the achievement of certain regulatory milestones. In addition to the foregoing contingent payments, Amneal has agreed to pay Kashiv certain royalty payments equal to an escalating percentage of aggregate annual net sales for certain pharmaceutical products.Related Link: The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off IGM In-Licenses Cancer Drug From Sweden's Medivir For Up To $352.5M IGM Biosciences Inc (NASDAQ: IGMS) announced that it has entered into an exclusive license agreement with Medivir AB through which IGM will receive global, exclusive development and commercialization rights for the cancer drug birinapant.The combination of IGM-8444, an IgM antibody targeting death receptor 5 being developed by IGM, and birinapant has been shown to enhance anti-tumor activity preclinically.IGM will pay $1 million upon signing the agreement, followed by an additional $1.5 million when birinapant is included by IGM in clinical Phase I studies. The terms of the agreement also entitle Medivir to receive development and regulatory milestone payments up to a total of approximately $350 million, plus tiered royalties from the mid-single digits up to mid-teens on net sales.Adaptive Biotechnologies, AstraZeneca To Collaborate On Mapping Immune Response To Cancer Antigens Adaptive Biotechnologies Corp (NASDAQ: ADPT) announced a translational collaboration with AstraZeneca plc (NASDAQ: AZN) to investigate the use of immunoSEQ T-MAP -- a product that combines the sequencing and mapping capabilities of Adaptive's proprietary immune medicine platform to map T-cell receptors to antigens -- across AstraZeneca's oncology portfolio.Adaptive stands to receive quarterly payments plus sequencing and data mapping fees. In addition, AstraZeneca has an option to enter into a separate agreement with Adaptive for the development and commercialization of a companion diagnostic or therapeutic application based on T-MAP data.La Jolla Licenses European Rights To 2 Drugs For Up To $122M La Jolla Pharmaceutical Company (NASDAQ: LJPC) announced an exclusive licensing agreement with PAION AG for Giapreza and Xerava in the European Economic Area, the U.K. and Switzerland for an upfront cash payment of $22.5 million and potential commercial milestone payments of up to $109.5 million. La Jolla will also receive double-digit tiered royalty payments based on net sales.La Jolla shares were up 61.42% to $6.36 in premarket trading Tuesday.Merck's Pneumococcal Conjugate Vaccine Accepted For Priority ReviewMerck & Co., Inc. (NYSE: MRK) said the FDA accepted for priority review a BLA for V114, its investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in adults 18 and older. The FDA set a PDUFA goal date of July 18.In premarket trading Tuesday, Merck shares were adding 0.12% to $85.10.Pre-Announcements GenMark Diagnostics, Inc (NASDAQ: GNMK) preannounced full-year 2020 revenues of about $171 million, up 95% year-over-year, with ePlex revenues climbing 155% to $152 million.Fourth-quarter revenues are expected at $50 million, an 84% increase from a year-ago. Analysts, on average, estimate full-year revenues of $167.48 million and fourth-quarter revenues of $45.87 million.The stock was up 5.3% premarket at $16.30. Orthopediatrics Corp (NASDAQ: KIDS) announced preliminary fourth-quarter revenues of $21.7 million, up 14% year-over-year, and full-year revenues $73.8 million, representing annual growth of 2%. The consensus estimates call for revenues of $20.31 million for the quarter and $72.46 million for the full year.Offerings RedHill Biopharma Ltd (NASDAQ: RDHL) said it has entered into an underwriting agreement with H.C. Wainwright & Co. for the purchase on a firm commitment basis of 1.28 million ADSs at a price of $7.84 per ADS. The closing of the offering is expected to occur on or about Jan. 14, subject to satisfaction of customary closing conditions.The stock was down 7.58% premarket at $8.05. Theratechnologies entered into an agreement with Mackie Research Capital as the lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters, pursuant to which the underwriters have agreed to purchase, on a bought-deal basis, 14.55 million units of the company for aggregate gross proceeds of $40 million at a price of $2.75 per unit.The stock was declining 5.66% premarket to $3. MediciNova, Inc. (NASDAQ: MNOV) said it has entered into a securities purchase agreement pursuant to which MediciNova has agreed to issue $20 million in shares of its common stock to 3D Opportunity Master Fund, a fund managed by 3D Investment Partners, in a private placement transaction.MediciNova intends to use the proceeds received from the private placement primarily for its clinical programs.Polarityte Inc (NASDAQ: PTE) said it has entered into a securities purchase agreement with a single, health care-dedicated institutional investor providing for the purchase and sale of 9.09 million shares of its common stock, or pre-funded warrants to purchase common stock in lieu thereof, and accompanying warrants to purchase up to 9.09 million shares of common stock.The stock eased 5.62% to $1.18 in premarket trading Tuesday.Related Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates See more from Benzinga * Click here for options trades from Benzinga * The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off * The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics
    GlobeNewswire

    Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics

    Multi-year, pan-portfolio deal extends Adaptive’s proprietary immunoSEQ T-MAP offering, originally launched for COVID-19, into oncology This transaction highlights the value of immune receptor data generated by Adaptive’s proprietary immune medicine platformSEATTLE, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a translational collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to investigate the use of immunoSEQ T-MAP, a product that combines the sequencing and mapping capabilities of Adaptive’s proprietary immune medicine platform to map T-cell receptors (TCRs) to antigens, across AstraZeneca’s oncology portfolio.         Under this collaboration, AstraZeneca will provide biological samples from patients with cancer; Adaptive will sequence these samples and deliver TCR-antigen mapping data using its growing and dynamic clinical immunomics database of more than 58 billion immune cell receptors and thousands of antigens. This mapping data may inform signatures of immune response (or resistance) to cancer therapies which may provide information to guide treatment decisions. Additionally, mapping of unique TCRs to antigens at scale can provide powerful information regarding the potential for early and accurate detection of a disease and the specificity of a given patient’s immune response to therapy.“We continue to demonstrate that specific T-cell immune receptor data can be utilized to inform the diagnosis and treatment for most diseases,” said Sharon Benzeno, Chief Business Development Officer, Adaptive Biotechnologies. “We are thrilled to partner with AstraZeneca to realize the value of antigen-specific T-cell response data across their portfolio of transformative cancer medicines.”Adaptive will receive from AstraZeneca quarterly payments plus sequencing and data mapping fees. In addition, AstraZeneca has an option to enter into a separate agreement with Adaptive for the development and commercialization of a companion diagnostic or therapeutic application based on T-MAP data. Specific financial terms of the agreement will not be disclosed.The scope of this non-exclusive, pan-portfolio oncology collaboration may be expanded to cover additional therapeutic areas, including autoimmunity and infectious diseases.About Adaptive Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech.Forward Looking Statements This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.ADAPTIVE MEDIA Beth Keshishian 917-912-7195 media@adaptivebiotech.comADAPTIVE INVESTORS Karina Calzadilla, Vice President, Investor Relations 201-396-1687 Carrie Mendivil, Gilmartin Group investors@adaptivebiotech.com

  • Billionaire Andreas Halvorsen’s Top 10 Stock Picks
    Insider Monkey

    Billionaire Andreas Halvorsen’s Top 10 Stock Picks

    In this article, we presented billionaire Andreas Halvorsen’s top 10 stock picks. Click to skip ahead and see Billionaire Andreas Halvorsen’s Top 5 Stock Picks. The billionaire Andreas Halvorsen’s Viking Global Investors LP has beaten the broader market index in 2020 by returning 25% after management and performance fees. This is not the first time […]